Avadel Pharmaceuticals Plc

Avadel Pharmaceuticals Plc company information, Employees & Contact Information

Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. We are disrupting paradigms where it’s needed most – starting with narcolepsy. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. At Avadel, our core values foster an atmosphere of transformation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with sleep disorders. Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.

Company Details

Employees
229
Founded
-
Address
Block 10-1, Blanchardstown Corporate Park,
Phone
(636) 449-1830
Email
in****@****del.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
avadel.com
Keywords
Manager jobs.
HQ
Dublin
Looking for a particular Avadel Pharmaceuticals Plc employee's phone or email?

Avadel Pharmaceuticals Plc Questions

News

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PR Newswire

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc PR Newswire

Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding - Yahoo Finance

Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding Yahoo Finance

Avadel: Mispriced Leader In Once-Nightly Sleep Therapies - Seeking Alpha

Avadel: Mispriced Leader In Once-Nightly Sleep Therapies Seeking Alpha

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) The Manila Times

Avadel Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results - Quiver Quantitative

Avadel Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results Quiver Quantitative

161,600 Options Granted — Avadel awards 10-year options to 7 new employees with 4-year vesting - Stock Titan

161,600 Options Granted — Avadel awards 10-year options to 7 new employees with 4-year vesting Stock Titan

Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating - Seeking Alpha

Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating Seeking Alpha

$1.7 Million in Sleep Research Grants: How Avadel's 5-Year AASM Partnership is Transforming Sleep Medicine - Stock Titan

$1.7 Million in Sleep Research Grants: How Avadel's 5-Year AASM Partnership is Transforming Sleep Medicine Stock Titan

Avadel Partners with XWPharma to Commercialize Sleep Medication - Pharmaceutical Executive

Avadel Partners with XWPharma to Commercialize Sleep Medication Pharmaceutical Executive

REFRESH Study to Test Real-World Clinical Effectiveness of Once-Nightly Sodium Oxybate - NeurologyLive

REFRESH Study to Test Real-World Clinical Effectiveness of Once-Nightly Sodium Oxybate NeurologyLive

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd - The Manila Times

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd The Manila Times

Avadel Pharmaceuticals Receives Federal Circuit Approval to Develop LUMRYZ for Idiopathic Hypersomnia and Other Indications Beyond Narcolepsy - Nasdaq

Avadel Pharmaceuticals Receives Federal Circuit Approval to Develop LUMRYZ for Idiopathic Hypersomnia and Other Indications Beyond Narcolepsy Nasdaq

Lumryz Approval Expanded to Include Pediatric Narcolepsy - Medical Professionals Reference

Lumryz Approval Expanded to Include Pediatric Narcolepsy Medical Professionals Reference

Salt-Free Sleep Drug Deal: Avadel Pharma Expands Portfolio with $20M Valiloxybate License for Narcolepsy - Stock Titan

Salt-Free Sleep Drug Deal: Avadel Pharma Expands Portfolio with $20M Valiloxybate License for Narcolepsy Stock Titan

FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy - NeurologyLive

FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy NeurologyLive

Avadel (NASDAQ: AVDL) and Jazz end litigation; LUMRYZ licensed, royalties through 2036 - Stock Titan

Avadel (NASDAQ: AVDL) and Jazz end litigation; LUMRYZ licensed, royalties through 2036 Stock Titan

FDA Approves Sodium Oxybate for Cataplexy, Excessive Daytime Sleepiness in Pediatric Narcolepsy - HCPLive

FDA Approves Sodium Oxybate for Cataplexy, Excessive Daytime Sleepiness in Pediatric Narcolepsy HCPLive

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA - GlobeNewswire

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA GlobeNewswire

Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz - Seeking Alpha

Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz Seeking Alpha

Avadel Pharmaceuticals Announces FDA Acceptance of New Drug - GlobeNewswire

Avadel Pharmaceuticals Announces FDA Acceptance of New Drug GlobeNewswire

FDA Approves Expanded Indication for Lumryz in Pediatric Patients with Narcolepsy - Pharmaceutical Executive

FDA Approves Expanded Indication for Lumryz in Pediatric Patients with Narcolepsy Pharmaceutical Executive

FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy - NeurologyLive

FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy NeurologyLive

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9 - Stock Titan

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9 Stock Titan

Lumryz Demonstrates Superiority Over Oxybate Treatments in Narcolepsy - Pharmaceutical Executive

Lumryz Demonstrates Superiority Over Oxybate Treatments in Narcolepsy Pharmaceutical Executive

Avadel Pharmaceuticals Announces Pricing of Public Offering - GlobeNewswire

Avadel Pharmaceuticals Announces Pricing of Public Offering GlobeNewswire

Nouress Approved to Meet Nutritional Requirements of Neonates Requiring TPN - Medical Professionals Reference

Nouress Approved to Meet Nutritional Requirements of Neonates Requiring TPN Medical Professionals Reference

Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc - GlobeNewswire

Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc GlobeNewswire

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis - MarketBeat

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis MarketBeat

AVDL Stock Price and Chart — NASDAQ:AVDL - TradingView

AVDL Stock Price and Chart — NASDAQ:AVDL TradingView

Top Avadel Pharmaceuticals Plc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant